SecurityMTNB / Matinas Biopharma Holdings, Inc. (576810105)
President and CEOJabbour Jerome D
IndustryPharmaceutical Preparations
Institutional Owners47
Institutional Shares11,433,973 - 12.16%
Common Shares Outstanding94,035,562 shares (as of 2018-03-31)
Institutional Value$ 24,204,000 USD

Institutional Stock Ownership and Shareholders()

MTNB / Matinas Biopharma Holdings, Inc. Institutional Ownership

Matinas Biopharma Holdings, Inc. (AMEX:MTNB) has 47 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 11,433,973 shares. Largest shareholders include Vanguard Group Inc, BlackRock Inc., State Street Corp, Royal Bank Of Canada, Raymond James Financial Services Advisors, Inc., Northern Trust Corp, Geode Capital Management, Llc, Alliance Wealth Management Group, IFP Advisors, Inc, and Bridgeway Capital Management Inc.
Matinas Biopharma Holdings, Inc. (AMEX:MTNB) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

Embed this chart! (it updates automatically)
<a href="https://fintel.io/so/us/mtnb"><img src="https://images.fintel.io/us-mtnb-so.png" alt="MTNB / Matinas Biopharma Holdings, Inc. Institutional Ownership"><a>

File DateFormInvestor Opt Prev
Shares
Current
Shares
Change
(Percent)
Prev Value
($1000)
Current Value
($1000)
Change
(Percent)
2018-05-15 13F-HR AQR CAPITAL MANAGEMENT LLC 14,452 0 -100.00 17 0 -100.00
2018-05-11 13F-HR CITADEL ADVISORS LLC 24,604 19
2018-05-15 13F-HR VANGUARD GROUP INC 2,699,548 2,784,159 3.13 3,131 2,129 -32.00
2018-05-14 13F-HR TIAA CREF INVESTMENT MANAGEMENT LLC 164,004 164,004 0.00 190 125 -34.21
2018-05-15 13F-HR MANUFACTURERS LIFE INSURANCE COMPANY, THE 12,100 0 -100.00 14 0 -100.00
2018-05-09 13F-HR IFP Advisors, Inc 251,172 251,172 0.00 291 192 -34.02
2018-05-15 13F-HR Ameritas Investment Partners, Inc. 4,634 4,634 0.00 5 4 -20.00
2018-05-10 13F-HR JP Morgan Chase & Co 59,103 58,160 -1.60 68 44 -35.29
2018-05-02 13F-HR RHUMBLINE ADVISERS 42,905 43,605 1.63 50 33 -34.00
2018-05-15 13F-HR BANK OF AMERICA CORP /DE/ 7,668 4,982 -35.03 9 4 -55.56
2018-05-14 13F-HR Virtu Financial LLC 106,146 0 -100.00 123 0 -100.00
2018-05-15 13F-HR UBS Group AG 10,934 0 -100.00 13 0 -100.00
2018-05-17 13F-HR Legal & General Group Plc 13,803 13,803 0.00 16 11 -31.25
2018-05-15 13F-HR Voya Investment Management LLC 33,096 33,096 0.00 38 25 -34.21
2018-05-14 13F-HR Commonwealth Equity Services, Llc. 10,200 10,200 0.00 12 7 -41.67
2018-07-03 13F-HR NEVILLE RODIE & SHAW INC 17,500 8
2018-04-16 13F-HR Raymond James Financial Services Advisors, Inc. 659,890 665,120 0.79 765 509 -33.46
2018-05-15 13F-HR CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM 103,046 103,046 0.00 120 79 -34.17
2018-05-14 13F-HR ALLIANCEBERNSTEIN L.P. 14,200 14,200 0.00 16 11 -31.25
2018-05-07 13F-HR AMERICAN INTERNATIONAL GROUP INC 44,034 41,786 -5.11 51 32 -37.25
2018-05-07 13F-HR STATE OF WISCONSIN INVESTMENT BOARD 36,000 36,000 0.00 42 28 -33.33
2018-05-10 13F-HR NEW YORK STATE COMMON RETIREMENT FUND 56,100 56,100 0.00 65 43 -33.85
2018-05-09 13F-HR Private Advisor Group, LLC 17,516 13
2018-05-09 13F-HR NORTHERN TRUST CORP 638,557 656,322 2.78 741 502 -32.25
2018-05-07 13F-HR HYMAN CHARLES D 79,800 79,800 0.00 93 61 -34.41
2018-05-09 13F-HR BlackRock Inc. 2,530,508 2,521,640 -0.35 2,935 1,928 -34.31
2018-05-14 13F-HR MORGAN STANLEY 132,818 152,147 14.55 154 116 -24.68
2018-05-03 13F-HR SG Americas Securities, LLC 43,126 0 -100.00 50 0 -100.00
2018-01-24 13F-HR Yellowstone Partners, LLC 143,914 143,914 0.00 190 167 -12.11
2018-05-15 13F-HR GEODE CAPITAL MANAGEMENT, LLC 529,177 543,804 2.76 613 415 -32.30
2018-05-18 13F-HR/A ROYAL BANK OF CANADA 334,393 784,154 134.50 387 599 54.78
2018-05-14 13F-HR/A CITADEL ADVISORS LLC 44,736 24,604 -45.00 52 19 -63.46
2018-05-15 13F-HR STATE STREET CORP 844,990 865,702 2.45 980 664 -32.24
2018-05-15 13F-HR Tower Research Capital LLC (TRC) 21,181 0 -100.00 25 0 -100.00
2018-05-07 13F-HR SCHWAB CHARLES INVESTMENT MANAGEMENT INC 89,500 89,500 0.00 104 69 -33.65
2018-05-14 13F-HR UNITED SERVICES AUTOMOBILE ASSOCIATION 11,213 9
2018-05-15 13F-HR Bank of New York Mellon Corp 175,325 176,849 0.87 203 135 -33.50
2018-05-15 13F-HR Fore Capital, Llc 10,000 8
2018-05-02 13F-HR WELLS FARGO & COMPANY/MN 77,753 83,562 7.47 90 64 -28.89
2018-02-16 13F-HR/A Commonwealth Equity Services, Inc 10,200 10,200 0.00 17 13 -23.53
2018-05-15 13F-HR DEUTSCHE BANK AG\ 148,042 74,138 -49.92 171 56 -67.25
2018-05-03 13F-HR AMERICAN CENTURY COMPANIES INC 133,220 0 -100.00 155 0 -100.00
2018-05-15 13F-HR BRIDGEWAY CAPITAL MANAGEMENT INC 189,000 189,000 0.00 219 145 -33.79
2018-05-15 13F-HR CREDIT SUISSE AG/ 18,575 24,215 30.36 22 19 -13.64
2018-05-15 13F-HR SUSQUEHANNA INTERNATIONAL GROUP, LLP 0 18,448 0 14
2018-05-15 13F-HR GOLDMAN SACHS GROUP INC 54,537 15,422 -71.72 63 12 -80.95
2018-05-15 13F-HR GUGGENHEIM CAPITAL LLC 20,736 21,364 3.03 23 16 -30.43
2018-05-15 13F-HR Paloma Partners Management Co 17,400 17,400 0.00 20 13 -35.00
2018-05-03 13F-HR MEEDER ASSET MANAGEMENT INC 2,035 1,884 -7.42 2 1 -50.00
2018-05-15 13F-HR BARCLAYS PLC 10,369 13,620 31.35 12 11 -8.33
2018-05-15 13F-HR Parallax Volatility Advisers, L.P. 16,128 0 -100.00 19 0 -100.00
2018-05-15 13F-HR TWO SIGMA SECURITIES, LLC 15,165 0 -100.00 18 0 -100.00
2018-05-23 13F-HR/A Alliance Wealth Management Group 400,826 400,826 0.00 465 307 -33.98
2018-05-11 13F-HR BNP PARIBAS ARBITRAGE, SA 16,622 20,127 21.09 19,282 15,393 -20.17
2018-05-10 13F-HR FIRST REPUBLIC INVESTMENT MANAGEMENT, INC. 0 30,000 0 23
2018-05-14 13F-HR TEACHERS ADVISORS INC 96,350 96,350 0.00 112 74 -33.93
2018-05-11 13F-HR CITIGROUP INC 6,632 14,081 112.32 8 35 337.50

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Related News Stories

Matinas Biopharma Holdings' (MTNB) CEO Jerry Jabbour on Q1 2018 Results - Earnings Call Transcript

2018-05-13 seekingalpha
Greetings, and welcome to the Matinas BioPharma Quarterly Update Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded. (10-1)

BRIEF-Matinas Biopharma Reports 2017 Financial Results

2018-03-26 reuters
* MATINAS BIOPHARMA HOLDINGS INC - BELIEVES THAT CASH ON HAND IS SUFFICIENT TO FUND OPERATIONS INTO SEPTEMBER 2018 Source text for Eikon: Further company coverage: (10-0)

CUSIP: 576810105